fenretinide + safingol

Fenretinide + safingol is an investigational combination therapy composed of two small molecules with distinct but potentially synergistic mechanisms of action. Fenretinide (4-HPR) is a synthetic retinoid that induces cytotoxicity in cancer cells primarily through the production of dihydroceramide, leading to apoptosis and other forms of cell death. Safingol is a lyso-sphingolipid and stereochemical-variant dihydroceramide precursor that acts as a protein kinase C inhibitor and modulates ceramide metabolism. Preclinical studies have shown that the combination enhances anti-tumor effects compared to either agent alone, likely due to their complementary actions on sphingolipid metabolism and induction of reactive oxygen species (ROS). The combination has been evaluated in phase I clinical trials for refractory solid tumors and lymphoma, where it demonstrated manageable toxicity but limited clinical activity[1][6]. The most common adverse event was hypertriglyceridemia attributed to the fenretinide lipid emulsion vehicle; cardiac events were observed at higher doses of safingol[1][6].